Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RepaGyn is a vaginal suppository formulated with sodium hyaluronate and several non-medicinal ingredients including aloe vera, centella asiatica, calendula officinalis, tea tree essential oil, semi-synthetic glycerides, and butylated hydroxytoluene (BHT). It is designed to relieve vaginal dryness and promote healing of the vaginal mucosa. The product is hormone-free and intended for use in cases of vaginal atrophy or dryness caused by menopause, stress, chemotherapy, or after invasive vaginal procedures. Each 2 g ovule contains 5 mg of sodium hyaluronate. RepaGyn has been used in several European countries for over a decade under various brand names[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RepaGyn.